All In Biotech

Drug Trial Radar · NCT05196399

Bioequivalence Study of Different Aprocitentan Tablet Formulations

A Single-center, Open-label, Randomized, Two-way Crossover Phase 1 Study to Compare the Single-dose Pharmacokinetics of Different Tablet Formulations of Aprocitentan in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Feb 2, 2022

Primary completion

Mar 27, 2022

Study completion Apr 7, 2022

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Jan 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose is to study the pharmacokinetics of aprocitentan (ACT-132577) using 2 different tablet formulations. The clinical pharmacology data will be used to determine bioequivalence of 2 different tablet formulations.

Conditions

  • Healthy Subjects

Interventions

  • Aprocitentan (Formulation A)Drug

    A single oral dose of 25 mg.

  • Aprocitentan (Formulation B)Drug

    A single oral dose of 25 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax) of aprocitentanTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
  2. The area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of aprocitentanTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
  3. Area under the plasma concentration-time curve from zero to infinity (AUC0-inf) of aprocitentanTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CEPHA s.r.o.

    Pilsen, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.